Abstracts Archive - Page 254 of 2425 - ACR Meeting Abstracts

Abstract Number: 1132 • ACR Convergence 2023
Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases
Wenhe Zhong, Jielian Lu, Dong Chen, Shiqun Zhang and Daiguo Deng, Guangzhou Fermion Technology Co., LTD, Guangzhou, China
Background/Purpose: Tyrosine Kinase 2 (TYK2) is a signaling protein within the Janus kinase (JAK) family. It plays a crucial role in transmitting signals from pro-inflammatory…
Abstract Number: 1263 • ACR Convergence 2023
Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases
Luis Vega Sevilla¹, Miguel Villarreal-Alarcon², Diana Paola Flores-Gutierrez³, Maria Corral-Trujillo⁴, Ricardo Juarez⁴, Ivan Hernandez Galarza⁵, Jesus Alberto Cardenas-De la Garza⁶ and Dionicio A. Galarza-Delgado², ¹Hospital Universitario UANL, Garcia, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁴Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵University Hospital, UANL, San Pedro Garza Garcia, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Depression is one of the most common psychiatric comorbidities in patients with rheumatic diseases. A study has shown that almost a third of patients…
Abstract Number: 1332 • ACR Convergence 2023
Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)
Gerd Burmester¹, Patrick Verschueren², Jerome AVOUAC³, Roberto F. Caporali⁴, Karen Bevers⁵, Neil Betteridge⁶, Thomas P.A. Debray⁷, Francesco De Leonardis⁸, Susana Romero Yuste⁹, Monia Zignani⁸ and James Galloway¹⁰, ¹Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ⁵Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁶Neil Betteridge Associates, London, United Kingdom, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹⁰King's College London, London, United Kingdom
Background/Purpose: The efficacy of filgotinib (FIL) for treating RA has been demonstrated in clinical trials. Real-world data are valuable to assess patient-reported outcomes such as…
Abstract Number: 0807 • ACR Convergence 2023
Inferring Disease Activity Scores and Low Disease Activity at Registry Visits Based on Structured and Narrative Data from Electronic Health Records
David Cheng¹, Dana Weisenfeld², Kumar Dahal², Qing Liu², Vidul Ayakulangara Panickan³, Mary Jeffway², Thany Seyok², Gregory McDermott², Michael Weinblatt⁴, Nancy Shadick⁵, Tianxi Cai⁶ and Katherine Liao², ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Real-world data including electronic health records (EHRs) are a promising resource for learning to optimize treatment strategies for rheumatoid arthritis (RA). A major challenge…
Abstract Number: 1329 • ACR Convergence 2023
R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis
Yan Chen¹, Sothy Yi¹, Vadim Markovtsov¹, Bhushan Samant¹, Andrew Chow¹, Esteban Masuda¹ and Simon Shaw², ¹Rigel Pharmaceuticals, Inc, South San Francisco, CA, ²Rigel Pharmaceuticals, Inc., South San Francisco, CA
Background/Purpose: The Toll-Like Receptor family (except TLR3) signal through IRAK4 and IRAK1 to produce an array of cytokines (including IL-6, IL-23 and TNFα in response…
Abstract Number: 0361 • ACR Convergence 2023
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
Leah Medrano and Alice Hoftman, David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…
Abstract Number: 1340 • ACR Convergence 2023
Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data
Stephanie Song¹, Michael George², Ted R Mikuls³, Bryant England⁴, Brian Sauer⁵, Grant Cannon⁶ and Joshua Baker², ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Janus kinase inhibitors (JAKi) have demonstrated substantial efficacy in decreasing symptoms and in reducing progressive joint damage in patients with rheumatoid arthritis (RA). In…
Abstract Number: 1137 • ACR Convergence 2023
Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease
Cristiana Sieiro Santos¹, Jose Luis Tandaipan², Diego Castillo², Laura Martínez Martínez², Helena Codes², Luis Sainz-Comas², Berta Paula Magallares-Lopez³, Patricia Moya², Anais Mariscal², Hye Sang Park², Ana Milena Millán Arciniegas², César Díaz-Torné², Ana Laíz Alonso², Sandra Ros², Susana Fernández², Hector Corominas⁴, Elvira Díez Álvarez⁵ and Iván Castellvi², ¹Complejo Asistencial Universitario de León, León, Spain, ²Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ³Department of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁴Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain, ⁵CAULE, León, Spain
Background/Purpose: Interstitial lung disease (ILD) is a frequent pulmonary manifestation in idiopathic inflammatory myopathies (IIM) (IIM-ILD) and considerably influences morbidity and mortality. Krebs von den…
Abstract Number: 1076 • ACR Convergence 2023
Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Olga Rusinovich¹, Enrique Calvo-Aranda², Claudia Maria Gomez², Patricio Cardoso Peñafiel², Pilar Navarro Alonso³, Miguel Cantalejo Moreira⁴, Alberto Diaz y Oca³, Pablo Navarro⁵, Maria Machattou⁵, Maria Alonso⁵, Carlota Navarro⁵, Carolina Merino⁵, Hilda Godoy⁶, Maria Carmen Barbadillo Mateos⁷, Carlos Isasi⁵, Maria Perez Ferro⁸, Jessica Polo⁹, Veronica Garcia¹⁰, Jose Luis Andreu-Sánchez¹¹, Jose Campos¹² and Jesus Sanz¹³, ¹Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, ²Hospital Universitario Infanta Leonor, Madrid, Spain, ³Fuenlabrada University Hospital, Madrid, Spain, ⁴Hospital Universitario de Fuenlabrada, Madrid, Spain, ⁵Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, ⁶Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁷Public, Madrid, Spain, ⁸Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁹Rey Juan Carlos University Hospital, Madrid, Spain, ¹⁰Ramon y Cajal University Hospital, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹²Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ¹³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Rituximab (RTX) is a murine/human chimeric monoclonal antibody directed against the CD20 receptor expressed on pre-B and mature B cells. Rituximab is used effectively…
Abstract Number: 1135 • ACR Convergence 2023
The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients
Alice Kwon¹, Audrey Liu¹, Sonali Narain², Elena Katzap³ and Galina Marder², ¹Northwell Health, Manhasset, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Northwell Health, Great NY, NY
Background/Purpose: Cardiac sarcoidosis is one of the most common causes of mortality from sarcoidosis. In this retrospective study, we describe prescribing patterns and compare outcomes between patients treated with conventional immunosuppressive therapies…
Abstract Number: 1091 • ACR Convergence 2023
Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care
Raphael Kirou, Cesar Avalos and Ellen Ginzler, SUNY Downstate Health Sciences University, Brooklyn, NY
Background/Purpose: Quality of care (QoC) in SLE patients has been studied by Schmajuk et al. (Arthritis Care Res2022), who developed six quality measures assessing blood…
Abstract Number: 1334 • ACR Convergence 2023
Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses
Marina Birck¹, Luck Lukusa², Michal Abrahamowicz³, Gilles Boire⁴, Denis Choquette⁵, Walter P. Maksymowych⁶ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²RI-MUHC, Montreal, QC, Canada, ³McGill University, Verdun, QC, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada
Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
Abstract Number: 1269 • ACR Convergence 2023
The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes
Gregory McDermott¹, Keigo Hayashi¹, Pierre-Antoine Juge², Ritu Gill¹, Suzanne Byrne¹, Staci Gagne¹, Kathleen Vanni¹, Emily Kowalski¹, Grace Qian¹, Katarina Bade³, Alene Saavedra¹, Yumeko Kawano¹, Michael Diiorio³, Taylor Wolfgang¹, Edy Kim¹, Paul Dellaripa³, Michael Weinblatt⁴, Nancy Shadick³, Tracy J. Doyle¹ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
Abstract Number: 1141 • ACR Convergence 2023
COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience
Vincent Luceño¹, Peter Paolo Daleon¹ and Sandra Navarra², ¹University of Santo Tomas Hospital, City of Manila, Philippines, ²University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) were associated with an increased risk for COVID-19 infection, worse clinical outcomes, and COVID-19- related deaths. Vaccines carry the…
Abstract Number: 1148 • ACR Convergence 2023
A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome
Ashmia Saif¹, Hafsa Nomani², Frank Hwang², Jie Yang² and Qingping Yao², ¹Stony Brook University Hospital, Syosset, NY, ²Stony Brook University, Stony Brook, NY
Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].